Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NIHR Health Technology Aassessment is funding a new study looking at the risks and benefits of first line osteoporosis medications (oral bisphosphonates) amongst patients suffering from chronic kidney disease, led by Associate Professor Daniel Prieto-Alhambra of NDORMS.

Around 3 million people suffer from osteoporosis in the UK and about 27% of those have at least moderate chronic kidney disease (CKD).

Osteoporosis weakens bones and makes them fragile and more likely to break. Currently, first line therapies for the prevention of the condition include oral bisphosphonates, a type of drug known to reduce the risk of fracture and improve bone density within 6 months of therapy. However, little is known about the impact of this type of drug on chronic kidney disease.

The new study, to start in December this year, will provide key information on the association between oral bisphosphonates and both the rates of fractures (benefit) and potential side effects amongst patients with different stages of CKD. This will benefit not only patients and but also the NHS: clarifying whether the use of this type of drug is safe and effective in patients with CKD will enable an informed decision on whether UK patients with CKD should be treated with these drugs.

Associate Professor Daniel Prieto-Alhambra says: "Patients with renal impairment have an increased risk of fractures. However, the most commonly used drugs to prevent these could have serious side effects for them. We will use data from thousands of patients with CKD who have been previously exposed to bisphosphonates to determine whether these medications are both safe and effective for them."

The study will use 'real life' data as routinely collected in NHS clinical practice, including primary and hospital care anonymised records for millions of UK people, ensuring the study fully represents the general population of patients. This will make our findings a key piece of information for clinicians treating and patients suffering from kidney impairment considering bisphosphonate therapy across the NHS.

You can read more about this study here.

 

This project is funded by the National Institute for Health Research Health Technology Assessment, with project number 14/36/02: Risks and benefits of bisphosphonate use in patients with chronic kidney disease: a population-based cohort study.

Similar stories

Immunology preprint reviews launched in Nature Reviews Immunology

Kennedy Main Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

A more tailored approach to treating psoriatic arthritis

Arthritis Botnar Funding Main

Dr Laura Coates has been awarded £1.8M from the National Institute for Health Research (NIHR) to explore the potential for precision medicine in the choice of biologics to reduce inflammation and pain in psoriatic arthritis.

Motion-capture to help children walk: Oxford team support new gait laboratory in Ethiopia

Main Orthopaedics and trauma

The Research at Oxford on Analysis of Motion (ROAM) team at the University of Oxford have supported CURE Ethiopia Children’s Hospital to develop and open a brand new gait laboratory, the first of its kind in the country and the only other active gait lab on the African continent outside of South Africa.

Professor Eleanor Stride recognised in New Year’s Honours list 2021

Awards Main

Statutory Professor of Biomaterials is awarded Officer of the Order of the British Empire (OBE) for services to Engineering

Drug may boost vaccine responses in older adults

Kennedy Main

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Living reviews launched by Oxford and Cardiff in the wake of COVID-19 research

Kennedy Main Research

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.